Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
May 31 2016 - 6:00AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and C. difficile infection, will be reporting
its first quarter financial results for the period ending 30 April
2016 on Thursday, 2 June 2016.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease DMD and the infectious disease Clostridium
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
| Summit
Therapeutics |
|
|
|
| Glyn Edwards
/ Richard Pye (UK office) |
|
|
Tel: +44 (0)1235 443
951 |
| Erik Ostrowski /
Michelle Avery (US office) |
|
|
+1 617 225 4455 |
| |
|
|
|
| Cairn Financial
Advisers LLP |
|
|
|
| (Nominated
Adviser) |
|
|
|
| Liam Murray / Tony
Rawlinson |
|
|
Tel: +44 (0)20 7148
7900 |
| |
|
|
|
| N+1
Singer |
|
|
|
| (Broker) |
|
|
|
| Aubrey Powell / Jen
Boorer |
|
|
Tel: +44 (0)20 7496
3000 |
| |
|
|
|
| MacDougall
Biomedical Communications |
|
|
|
| (US media contact) |
|
|
Tel: +1 781 235
3060 |
| Chris Erdman / Karen
Sharma |
|
|
cerdman@macbiocom.com / |
| |
|
|
ksharma@macbiocom.com |
| |
|
|
|
| Consilium
Strategic Communications |
|
|
|
| (Financial public
relations, UK) |
|
|
Tel: +44 (0)20 3709
5700 |
| Mary-Jane Elliott / Sue
Stuart / |
|
|
summit@consilium-comms.com |
| Jessica Hodgson /
Lindsey Neville |
|
|
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024
